Categories Earnings, Other Industries

Cushman & Wakefield Q3 loss narrowed on higher fee revenue

Commercial real estate services firm Cushman & Wakefield (CWK) reported a narrower loss in the third quarter helped by the increase in Fee revenue exceeding the increase in Fee-based operating expenses and a higher benefit from income taxes.

Net loss decreased to $48.7 million or $0.26 per share from $78.6 million or $0.55 per share in the previous year quarter. Adjusted earnings soared 181% to $0.45 per share.

Revenue grew 21% to $2.1 billion. Fee revenue increased 17% reflecting increases primarily in Leasing, Capital markets, and Property, facilities, and project management. Leasing Fee revenue increased 30% driven by an America’s increase of 33%, with the remainder of the Fee revenue growth primarily in EMEA.

Setback for Walmart as CEO of Flipkart quits over “personal misconduct”

Capital markets Fee revenue increased by 34% driven by America’s increase of 42%. Property, facilities and project management Fee revenue rose by 6% helped by an America’s rise of 5% with the remainder of the Fee revenue growth primarily in EMEA.

Gross contract costs, primarily in the Property, facilities and project management service line, increased $149.6 million driven by the $98.5 million impacts of the adoption of Topic 606. Foreign currency had a 3% unfavorable impact on Revenue.

Looking ahead into the full year 2018, the company now expects adjusted EBITDA in the range of $630 million to $650 million.

Shares of Cushman & Wakefield ended Tuesday’s regular session up 2.25% at $16.85 on the NYSE. The stock has fallen over 28% since its IPO listing on August 2, 2018.

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top